International Conference on Neurological disorder and Neuroimmunology
Montreal, Canada
Biography
Biography: Fadi Hamed
Abstract
Since the first human lung transplant in 1963, more than 40,000 lung transplant procedures have been performed worldwide. Although lung transplant is usually the last resort for patients and physicians when medical care has been exhausted, lung transplantation is now an accepted therapy for the management of a wide range of severe lung disorders, with evidence supporting quality of life and survival benefit for lung transplant recipients. Indications include diverse spectrum of pulmonary diseases affecting the airway, parenchyma and vasculature. In 2014, the International Society for Heart and Lung Transplantation (ISHLT) released an updated consensus document for the selection of lung transplant candidates, following 2 previous editions published in 1998 and 2006. This consensus includes indications for referral and listing according to disease and highlights absolute and relative contraindications. Despite all the advances in medical management post lung transplant, acute rejection and infection remain the major complications affecting survival in the first year post lung transplant. On the other hand, chronic lung allograft dysfunction in form of bronchiolitis obliterans syndrome (BOS) or restrictive allograft dysfunction (RAD) remains major cause of morbidity and mortality resulting in graft dysfunction, making 5 years survival of post-transplant patients around 50% in average.